The Difficulty in Defining the True High-Risk Smoldering Myeloma.

Early intervention trials have been initiated for the precursor disease smoldering myeloma (SMM). A recent study showed that genomic complexity varies widely among treated high-risk SMM patients and is associated with response to triplet therapy, suggesting that established clinical risk scores often fail to discriminate between stable and aggressive disease.